Sofosbuvir and velpatasvir for hcv genotype 1, 2, 4, 5, and 6 infection

J. J. Feld, I. M. Jacobson, C. Hode, T. Asselah, P. J. Ruane, N. Gruener, A. Abergel, A. Mangia, C. L. Lai, H. L Y Chan, F. Mazzotta, C. Moreno, E. Yoshida, S. D. Shafran, W. J. Towner, T. T. Tran, J. McNally, A. Osinusi, E. Svarovskaia, Y. ZhuD. M. Brainard, J. G. McHutchison, K. Agarwal, S. Zeuzem

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND A simple treatment regimen that is effective in a broad range of patients who are chronically infected with the hepatitis C virus (HCV) remains an unmet medical need. METHODS We conducted a phase 3, double-blind, placebo-controlled study involving untreated and previously treated patients with chronic HCV genotype 1, 2, 4, 5, or 6 infection, including those with compensated cirrhosis. Patients with HCV genotype 1, 2, 4, or 6 were randomly assigned in a 5:1 ratio to receive the nucleotide polymerase inhibitor sofosbuvir and the NS5A inhibitor velpatasvir in a once-daily, fixed-dose combination tablet or matching placebo for 12 weeks. Because of the low prevalence of genotype 5 in the study regions, patients with genotype 5 did not undergo randomization but were assigned to the sofosbuvir-velpatasvir group. The primary end point was a sustained virologic response at 12 weeks after the end of therapy. RESULTS Of the 624 patients who received treatment with sofosbuvir-velpatasvir, 34% had HCV genotype 1a, 19% genotype 1b, 17% genotype 2, 19% genotype 4, 6% genotype 5, and 7% genotype 6. A total of 8% of patients were black, 19% had cirrhosis, and 32% had been previously treated for HCV. The rate of sustained virologic response among patients receiving sofosbuvir-velpatasvir was 99% (95% confidence interval, 98 to >99). Two patients receiving sofosbuvir-velpatasvir, both with HCV genotype 1, had a virologic relapse. None of the 116 patients receiving placebo had a sustained virologic response. Serious adverse events were reported in 15 patients (2%) in the sofosbuvir-velpatasvir group and none in the placebo group. CONCLUSIONS Once-daily sofosbuvir-velpatasvir for 12 weeks provided high rates of sustained virologic response among both previously treated and untreated patients infected with HCV genotype 1, 2, 4, 5, or 6, including those with compensated cirrhosis. (Funded by Gilead Sciences; ClinicalTrials.gov number, NCT02201940.)

Original languageEnglish
Pages (from-to)2599-2607
Number of pages9
JournalNew England Journal of Medicine
Volume373
Issue number27
DOIs
Publication statusPublished - Dec 31 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Sofosbuvir and velpatasvir for hcv genotype 1, 2, 4, 5, and 6 infection'. Together they form a unique fingerprint.

Cite this